Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. Nektar's research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.
Read more about Nektar's technology »
View Nektar's R&D pipeline »
View approved products developed with Nektar technology »
Investor and Media Inquiries
Business Development and Partnering
FDA Approval of UCB's Cimzia® for Crohn's Disease Represents Latest Milestone for Nektar Polymer Chemistry Technology Platform
Cimzia® is the first and only PEGylated Fab' fragment of a humanized anti-TNF-alpha antibody approved by the FDA. Cimzia® is the ninth marketed product enabled by Nektar's (Nasdaq: NKTR) industry leading PEGylation technology platform. Nektar's partner UCB is also developing Cimzia® in Rheumatoid Arthritis and other autoimmune disease indications. Nektar is proud to support UCB in its development and commercialization of this very important therapeutic. Under the terms of the agreement between Nektar and UCB, Nektar will receive manufacturing revenues and royalties on global sales of Cimzia® for all indications.